Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Beersheva Mental Health Center Stanley Medical Research Institute |
---|---|
Information provided by: | Beersheva Mental Health Center |
ClinicalTrials.gov Identifier: | NCT00141947 |
In this proposed study, we aim to investigate the effects of Bexarotene (Targretin; LGD1069; 4-[1-{5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl} ethenyl] benzoic acid) on severity of psychopathology, cognitive impairment, and quality of life in schizophrenia patients in an open label trial. The rationale behind add-on oral bexarotene to ongoing antipsychotic treatment in schizophrenia patients is based on both the retinoid dysregulation hypothesis (Goodman, 1995) and the growth factors deficiency and synaptic destabilization hypothesis (Moises et al, 2002) of schizophrenia. In this clinical trial, a novel regimen of low dose bexarotene (Targretin, 75 mg/day) will be added for 6 weeks to the standard treatment of 15 schizophrenia patients on stable antipsychotic treatment. Participants will be assessed at baseline and after 2, 4 and 6 weeks of treatment. A battery of research instruments will be used for assessment of efficacy and safety (psychopathology, and side effects). In addition, cholesterol and triglyceride levels, liver and thyroid function tests and a blood cell count will be monitored at baseline and during therapy.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: bexarotene (Targretin) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | Safety and Efficacy of Add-On Oral Bexarotene to Antipsychotic Treatment in Schizophrenia Patients: An Open Label Trial |
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Vladimir Lerner, MD, PhD | 972-8-6401408 | lernervld@yahoo.com |
Contact: Chanoch Midownik, MD | 972-8-6401404 | chanoch_m@yahoo.com |
Israel | |
Beersheva Mental Health Center | Recruiting |
Beersheva, Israel | |
Contact: Vladimir Lerner, MD, PhD 972-8-6401408 lernervld@yahoo.com | |
Principal Investigator: Vladimir Lerner, MD, PhD | |
Shaar Manashe Mental Health Center | Recruiting |
Hadera, Israel | |
Contact: Michael Ritsner, MD 9728-627-8750 ritsner@shaar-menashe.org.il | |
Principal Investigator: Michael Ritsner, MD |
Principal Investigator: | Vladimir Lerner, MD, PhD | Ben-Gurion University of the Negev |
Principal Investigator: | Michael Ritsner, MD | Technion-Israel Institute of Technology (Haifa) |
Study ID Numbers: | BMHC-3775 |
Study First Received: | September 1, 2005 |
Last Updated: | October 24, 2005 |
ClinicalTrials.gov Identifier: | NCT00141947 |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
bexarotene schizophrenia psychopathology |
cognitive impairment quality of life open lable trial |
Schizophrenia Bexarotene Mental Disorders |
Quality of Life Psychotic Disorders Schizophrenia and Disorders with Psychotic Features |
Anticarcinogenic Agents Antineoplastic Agents Therapeutic Uses |
Physiological Effects of Drugs Protective Agents Pharmacologic Actions |